"Intractable no more: imagining the next wave of immunotherapeutics targeting the innate system"

About Speaker: Rabindra Tirouvanziam, PhD, serves as associate professor with tenure and Schinazi Family distinguished biomedical chair at Emory University, primary faculty within the Center for CF and Airways Disease Research at Children’s Healthcare of Atlanta, and adjunct associate professor in the Department of Biomedical Engineering at Georgia Tech and Emory.

Dr. Tirouvanziam earned his bioengineering degree at Agro Paris Tech (Paris, France) and his PhD in developmental biology and lung physiology at the College de France and CNRS (Paris, France). He trained as a postdoc in immunology and translational research at Stanford University (CA, USA) before joining Emory University as faculty in 2011.

Research in the Tirouvanziam lab includes patient- and model-based studies of cystic fibrosis, tuberculosis, COVID-19, cold tumors, and diabetes, focusing on innate immunity and metabolism. The Tirouvanziam lab emphasizes sample collection from patients and optimized in vitro and animal models combined with high-content analyses by cytometry, transcriptomics and epigenetics (for cells) as well as nanoparticle tracking analysis, proteomics and mass spectrometry (for extracellular vesicles and fluids) to delineate mechanisms of immunometabolic dysregulation and their relations to chronic disease.

The Tirouvanziam lab has been supported by NIH, NSF, DARPA, and the CF Foundation, as well as industry partnerships. As of January 2025, Dr. Tirouvanziam counts 18 members and has contributed over 100 papers, 240 abstracts and 6 patents. More information at: https://tirouvanziam-lab.com